Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06500884 |
| Consolidated Lead Sponsor | Johnson & Johnson / Janssen |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 210 participants (ESTIMATED) |
| Registered Start Date | 2024-08-26 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | Open Hospital Dossier -> |
| Colorado Blood Cancer Institute | Denver, CO | Open Hospital Dossier -> |
| Yale Cancer Center and Smilow Cancer Hospital | New Haven, CT | Open Hospital Dossier -> |
| Mount Sinai Hospital and Icahn School of Medicine | New York, NY | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.